Renal sympathetic denervation versus antiarrhythmic drugs for drug-resistant hypertension and symptomatic atrial fibrillation (RSDforAF) trial: study protocol for a randomized controlled trial by unknown
TRIALS
Qiu et al. Trials 2013, 14:168
http://www.trialsjournal.com/content/14/1/168STUDY PROTOCOL Open AccessRenal sympathetic denervation versus
antiarrhythmic drugs for drug-resistant
hypertension and symptomatic atrial fibrillation
(RSDforAF) trial: study protocol for a randomized
controlled trial
Min Qiu1, Yuehui Yin2† and Qijun Shan1*†Abstract
Background: Recently, catheter-based renal sympathetic denervation (RSD) has been verified to be safely used to
substantially reduce the levels of blood pressure, left ventricular hypertrophy, sleep apnea severity and
norepinephrine spillover, and improve glucose tolerance. All these pathological changes are recognized as
independent risk factors for the development and recurrence of atrial fibrillation (AF). A randomized, single-blind,
parallel-control, multicenter clinical trial is being conducted to compare RSD with antiarrhythmic drugs (AAD) in
patients with drug-resistant hypertension and symptomatic AF (RSDforAF trial).
Methods/design: Patients with drug-resistant hypertension and symptomatic AF will be randomized to RSD and
the drug treatment groups. Patients will be followed for 12 months until study closure. Up to 200 patients may be
enrolled in six medical centers in China. The primary objective is to study the effects of RSD on AF burden and
blood pressure in patients with hypertension and symptomatic AF.
Discussion: RSDforAF trial will test the hypothesis that RSD is superior to AAD in reducing AF burden and blood
pressure in patients with drug-resistant hypertension and symptomatic AF.
Trial registration: ClinicalTrials.gov, NCT01713270
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Atrial fibrillation (AF) is the most common arrhythmia,
with the estimated prevalence of AF being 0.4 to 1% in the
general population, increasing with age [1]. Hemodynamic
impairment and thromboembolic events related to AF
result in significant morbidity, mortality, and increase
medical financial burden. So far, treatment of AF remains
unsatisfactory. Pharmacological approaches for cardiover-
sion and maintaining sinus rhythm in patients with AF ap-
pear simple but are less efficacious. The major risk related* Correspondence: qjshan@njmu.edu.cn
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reproduction in any medium, provided the orto antiarrhythmia medicine is the considerable potential
drug toxicity and proarrhythmic effects. Cardiac radiofre-
quency catheter ablation of AF has developed rapidly in
recent years, but the success rate still remains relatively
low, especially in persistent AF patients. The higher recur-
rence of AF is also a big challenge in short- and long-term
follow-up. In addition, the complications associated with
AF ablation procedures are likely to result in prolonged
hospitalization, long-term disability or death. Hyperten-
sion is the most important risk factor for AF, and increases
the risk of thromboembolic complications [2]. In patients
with AF, aggressive treatment of hypertension may retard
or prevent the occurrence of AF. Recently, many clinical
researchers [3-6] have verified that catheter-based renal
sympathetic denervation (RSD) could be safely used to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trophy and sleep apnea severity, and improve glucose tol-
erance. Simultaneously, a marked reduction in muscle and
whole-body sympathetic nerve activity is apparent, with a
decrease in renal and whole-body norepinephrine spill-
over. Left ventricle hypertrophy, left atrium enlargement,
high norepinephrine level, glucose tolerance abnormality
and obstructive sleep apnea are all recognized as inde-
pendent risk factors for the development and recurrence
of AF [7]. Thus, we designed this randomized, parallel-
control, multicenter clinical study to demonstrate whether
RSD is superior to antiarrhythmic drugs (AAD) in redu-
cing AF burden and blood pressure in patients with drug-
resistant hypertension and symptomatic AF.
Methods
General
The RSDforAF trial is a randomized, controlled, parallel,
multicentre study. Patients with drug-resistant hyperten-
sion and symptomatic AF are randomly assigned to the
medical antiarrhythmic and antihypertensive treatment
group or the RSD group, with 50% of the patients
assigned to each treatment arm. The first patient was
randomized in July 2012. A total of 200 patients will be
included and followed for a period of 12 months afterTable 1 Study inclusion/exclusion criteria
Inclusion criteria E
1 Individual is ≥18 and ≤75 years of age 1
2 More than 6 months for definite primary hypertension 2
3 Individual has a systolic blood pressure ≥160 mmHg (≥150 mmHg for




4 Individual is adhering to a stable drug regimen, including three or
more antihypertensive medications of which one is a diuretic, for a
minimum of 14 days prior to enrollment
4
5 At least 30 seconds on a rhythm strip in an ECG record and at least 1







6 Paroxysmal and persistent AF individual 6
p
b










Ainclusion. Enrollment is expected to be completed
by October 2014. This study is designed to assess the
safety and efficacy of RSD in patients with hypertension
and symptomatic AF. The trial is registered at www.
clinicaltrials.gov, registry number: NCT01713270. The
independent medical ethics committee of the First Affili-
ated Hospital of Nanjing Medical University has approved
this RSDforAF trial protocol, with the approval number
2012-SR-080. The institutional review board of each par-
ticipating institution approved the study protocol and all
the patients will provide written informed consent. All the
procedures of this study are under the monitor of our hos-
pital ethics committee.
Patients
Adult patients who meet all inclusion/exclusion criteria
(Table 1), have documented symptomatic AF (including
paroxysmal and persistent AF), and have had at least
one episode during the preceding 6 months are eligible
for this study. Patients should be adhering to a stable
antihypertensive drug regimen, including three or more
antihypertensive medications of which one is a diuretic,
for a minimum of 14 days prior to enrollment. If, when
considering a patient’s baseline blood pressure, investiga-
tors feel that there are medication manipulations thatxclusion criteria
Secondary and white-coat hypertension
Permanent AF individual
Thrombus in left atrial appendage found by transesophageal
chocardiography
Individual with severely enlarged left atria ≥55 mm
Individual has experienced renal artery stenosis, or a history of prior
enal artery intervention including balloon angioplasty or stenting, or
neligible conditions seen on renal artery computed tomography
ngiogram inspection such as double renal artery on one side, renal
rtery length ≤2 cm, diameter ≤4 mm, and distortion at incept sect
Individual has experienced a definite acute coronary syndrome in the
ast 3 months, or a cerebrovascular accident and alimentary canal
leeding within 3 months
Individual has experienced sick sinus syndrome
reversible causes of AF, including alcohol abuse, surgery, electrocution,
yocadial infarction, pericarditis, myocarditis, pulmonary embolism or
ther pulmonary diseases, hyperthyroidism, and other metabolic
isorders
structural heart diseases such as congenital, valvular heart diseases and
inds of cardiomyopathy
0 Individual is pregnant or nursing
1 Mental disorders - individual cannot complete follow-up or one the
esearcher thinks is unfit to be included in this study
F, atrial fibrillation; ECG, electrocardiogram.
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should be made prior to evaluation for enrollment. If
such changes are made, they must be allowed to stabilize
for at least 2 weeks, and a screening blood pressure
measurement must be repeated on the new medication
regimen to determine if the patient qualifies for the
study. As long as the participants are included, they
should follow the research scheme for follow-up visits
and other requirements. The enrollment cascade and
follow-up procedure are presented in Figure 1.
Baseline evaluation and randomization
Prior to enrollment, patients will provide signed in-
formed consent and undergo a full baseline evaluation,
including physical examination, medical history, me-
dicine, New York Heart Association functional class,
12-lead electrocardiogram, 24-hour ambulatory electro-
cardiogram (Holter), 24-hour ambulatory blood pressure
monitoring, apnea-hypopnea index, pulse wave velocity,
quality of life (using Short Form-36 quality-of-life ques-
tionnaire), echocardiogram, renal artery CT imaging,
transesophageal echocardiography (only persistent AF
patients), and blood testing (serum creatinine, blood
lipid, glycosylated hemoglobin, fasting blood glucose).
The echocardiogram is performed to measure left ven-
tricular ejection fraction, left ventricular end-diastolic
diameter, interventricular septum and left atriumFigure 1 The enrollment cascade and follow-up procedure.
AAD, Antiarrthymic drugs; ABPM, Ambulatory blood pressure
monitoring; AF, Atrial fibrillation; AHI, Apnea-hypopnea index; CT,
Computed tomography; ECG, Electrocardiogram; Holter; ambulatory
cardiogram; PWV, Pulse wave velocity; RSD, Renal sympathetic
denervation; SF-36, Short Form-36 quality-of-life questionnaire.diameter. All the included patients should have no se-
vere mitral valve insufficiency, and no very large left
atrium (≥55 mm). Renal artery CT imaging scans the
suitability of the anatomy for treatment - anatomic eligi-
bility is defined as bilateral single main renal arteries
>4 mm in diameter and >20 mm in length, without sig-
nificant stenosis or other abnormality.
Patients meeting all selection criteria, and having ana-
tomic eligibility documented by renal artery imaging will
be randomized. Randomization will be stratified by study
center and will be at a 1:1 ratio for the RSD group to the
drug treatment group. To obtain nonbiased information
and perform nonbiased assessments, clinicians and their
staff who collect and assess system data are blinded to
the treatment. Unblinded clinicians and staff will be re-
sponsible for randomization, intervention processes, and
monitoring system performance. Using the intention-to
-treat analysis method of this study, these patients will
be followed in their original randomization assignment.
Intervention
Renal sympathetic denervation group
The technique of renal denervation has recently been
described by Ahmed and colleagues [8]. After standard
femoral vascular access, contrast renal angiography was
performed to localize and assess the renal arteries for ac-
cessibility and appropriateness for RSD. Once the anat-
omy was deemed acceptable, the internally irrigated
radiofrequency ablation catheter (Celcius Thermocool,
Biosense Webster, Diamond Bar, CA, USA) was intro-
duced into each renal artery. This was then maneuvered
within the renal artery to allow energy delivery in a
circumferential, longitudinally staggered manner to
minimize the chance of renal artery stenosis. About four
to eight ablations at 10 W for 60 seconds each were
performed in both renal arteries. During ablation, the
catheter system monitored tip temperature and impe-
dance, altering radiofrequency energy delivery in re-
sponse to a predetermined algorithm. Visceral pain at
the time of energy delivery was managed with 0.05 to
0.1 mg intravenous fentanyl. After renal sympathetic
denervation, patients with persistent AF accepted direct-
current cardioversion immediately.
If clinically indicated, class IC AAD treatment
(propafenone) is a first-line therapy for patients without
contraindications, otherwise amiodarone is the drug of
choice, and also metoprolol may be prescribed. If ne-
cessary, AAD can be supplemented by agents such as
digoxin, diltiazem and metoprolol that slow the atrio-
ventricular conduction. Combination of several AAD is
not allowed. Recommended drugs are shown in Table 2.
After 3 months, AAD treatment is discontinued. Efforts
will be made to document any relapse of symptomatic
arrhythmia by either 12-lead electrocardiogram or
Table 2 Recommended antiarrhythmic drugs in the study
1st choice 2nd choice 3rd choice
Propafenone Amiodarone Metoprolol
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tored closely throughout the study period in both treat-
ment arms.
Antihypertensive medications are intended to be
maintained at baseline doses (in both RSD and the drug
treatment group) for at least 6 months to evaluate the
primary endpoint of effectiveness of RSD without me-
dication changes confounding the results. However, in
cases where medication changes are considered medi-
cally necessary (for example, significant blood pressure
lowering or adverse events directly related to blood pres-
sure or blood pressure medications), alteration may be
made as necessary.
Drug treatment group
Patients in the drug treatment group will be followed-up
at 3, 6, 9 and 12 months after randomization. All the
patients in this group will take their baseline antihyper-
tensive medication at the original doses, without any
changes except when medically required. AAD treat-
ment is consistent in both arms.
Antithrombotic strategies
Oral anticoagulation (warfarin, INR 2.0 to 3.0) is
recommended for at least 2 months in both arms [7]. After
direct-current cardioversion fails in patients with persistent
AF, anticoagulation therapy is continued throughout the
study period to obtain a stable INR of 2.0 to 3.0.
Follow-up and data management
Prior to discharge, the research staff shall review study
requirements with the patient to ensure compliance with
the follow-up schedule. Figure 1 lists the work-ups and
procedures required at each follow-up time for the drug
treatment and RSD groups.
Individual patient log-books are filled in with the fol-
lowing data: (i) daily home blood pressure, heart rate
and medications (at least twice a week), (ii) episodes of
symptomatic arrhythmia, and (iii) cause of changing or
stopping medicine.
All study data will be recorded onto case report forms.
The principal investigator remains responsible for the
accuracy and integrity of all data entered on case report
forms.
Primary endpoints
The primary endpoint of this study is to demonstrate
the effect of RSD on AF burden in patients with hyper-
tension and symptomatic AF.Secondary endpoints
The secondary endpoints consist of the change in office
systolic blood pressure from baseline to 12 months post-
randomization, changes in cardiac structure and func-
tion by echocardiogram (include left ventricular ejection
fraction, left ventricular end-diastolic diameter, inter-
ventricular septum, left atrium diameter), autonomic
nerve function (heart rate variability by Holter), fasting
blood glucose, glycated hemoglobin, blood lipid, apnea-
hypopnea index, pulse wave velocity and quality of life.
Sample size and statistical analysis
It is assumed that 27.75% of AAD-treated patients [7]
and 40% of RSD patients [9] will be AF-free after 1 year,
and the two groups obey a binomial distribution and
have the same variance, each treatment arm including
76 patients. By two-tailed binomial tests, the difference
between the two groups can be detected with a power of
90%. To account for an approximate 20% premature
withdrawal rate prior to the 12-month time point, 180
patients will be randomized. As discussed above, it is
expected that approximately 200 patients will be en-
rolled into the baseline phase in order to achieve 180
randomized patients. All analyses will be carried out
according to the intention-to-treat-principle.
Adverse events
This is a fairly new technique and the information avai-
lable so far indicates it is very safe. No death has oc-
curred and there has been no documented lasting
damage to a kidney. The most common side effect we
have observed is bruising at the groin. Other rare but
potentially more serious side effects that have been
described are as follows:
1. Acute renal artery dissection. This can usually be
dealt with by placing a stent in the damaged artery.
2. Persistent abdominal pain lasting beyond the time of
the procedure.
3. Low heart rate.
4. Large drop in blood pressure. This may require
patients to stay in hospital for a few days to adjust
their medication.
5. Damage to the artery in the groin. This occurs in
about 1% of cases. Blood transfusion or rarely a
small procedure or operation to the artery may be
required.
6. Risk of failure to respond to renal sympathetic
denervation in 10 to 15% of cases.
Other possible side effects that have not been seen with
RSD, but which can occur after any procedure where an
artery is catheterized include an allergic reaction to the
X‐ray contrast, or contrast-induced nephropathy.
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Cardiac catheter ablation for AF has become a very
commonly and widely accepted procedure in recent
years, but the low success rate and high recurrence after
procedure in the short and long term is disappointing. A
recent report of the long-term success rate in patients
with symptomatic drug-refractory AF ablated at a pres-
tigious institution was dismal at 23% after 6 years of
follow-up [10]. When Cosedis and colleagues [11] com-
pared radiofrequency catheter ablation with AAD the-
rapy as first-line treatment in patients with paroxysmal
AF, there was no significant difference between the abla-
tion and drug therapy groups in the cumulative burden
of AF over a period of 2 years. Furthermore, left atrial
ablation probably leads to serious complications, includ-
ing cardiac perforation, stroke, pulmonary vein stenosis,
and atrial esophageal fistula formation.
So far, the most common risk factor of AF is hyperten-
sion. Research on Chinese hospitalized patients revealed
that more than half of AF sufferers had the co-morbidity
of hypertension. Hypertension is associated with left
ventricular hypertrophy, impaired ventricular filling, left
atrial pressure increases, left atrial enlargement, and
slowing of atrial electrical conduction velocity. These
changes in cardiac structure and electrical characters,
also called remodeling, favor the development and main-
tenance of AF. AF itself increases the risk of thrombo-
embolic complications [2]. Based on 38-year follow-up
data from the Framingham Study, echocardiographic
predictors of AF include left atrial enlargement (39% in-
crease in risk per 5 mm increment) and left ventricular
wall thickness (28% per 4 mm increment) [12]. Another
study examined the impact of increasing atrial pressure
on pulmonary vein muscle sleeve activation, and found
that, as left atrial pressure was increased above
10 cmH2O, the left atrial–pulmonary vein junction be-
came the source of dominant rotors [13]. In addition,
the renin-angiotensin-aldosterone system activity in-
creased in hypertensive heart disease. Angiotensin II is a
well characterized profibrotic molecule, giving rise to
atrial fibrosis and conduction heterogeneity [14]. Lau
and colleagues [15] have confirmed that hypertension is
associated with early and progressive changes in atrial
remodeling. Atrial remodeling occurs at different time
domains in chronic hypertension with significant
electro-structural correlation of the remodeling cascade.
Antihypertensive treatment at an early stage may pre-
vent formation of a substrate capable of maintaining AF.
Sympathetic nerve activity is crucial for initiation and
maintenance of systemic hypertension. It plays an im-
portant role in the development and maintenance of AF.
Animal models indicated that beta-adrenergic stimula-
tors agents (isoproterenol and adrenaline) can increase
the occurrence rate of AF by programmed electricalstimulation [16,17]. In a study by Oraland and colleagues
[18], among the 80 patients with paroxysmal AF, persist-
ent AF was induced in 67 patients (84%) by iso-
proterenol. Recently, clinical studies have verified that
metoprolol was effective in preventing relapse into AF
or atrial flutter after cardioversion of persistent AF
[19,20]. Both local and international scholars found
that significant nerve sprouting and sympathetic
hyperinnervation were present in animal models of
sustained AF produced by prolonged right atrial
pacing. Over-activity and inhomogeneous distribution
of regional sympathetic nerve play an important role
in AF induction [21,22].
Sympathetic activation of the heart increases calcium
entry and the spontaneous release of calcium from the
sarcoplasmic reticulum, and thus shortens the action po-
tential duration and atrial refractory period. Abnormal
intracellular calcium handling and short action potential
durations are key features of electrophysiological remod-
eling in AF [23]. In 2012, using animal models, Zhao
and colleagues [24] reported that episodes of AF could
be decreased by renal sympathetic denervation during
short-term rapid atrial pacing. This effect might have a
relationship with the decreased activity of the renin-
angiotensin-aldosterone system. In a swine model for
obstructive sleep apnea, renal denervation displayed an-
tiarrhythmic effects by attenuation of negative-tracheal
-pressure-induced atrial effective refractory period short-
ening [25]. Therefore, AF inducibility was reduced, and
simultaneously, postapneic blood pressure rises were
inhibited. In another study with 12 swine undergoing
renal denervation [26], heart rate as well as atrioven-
tricular nodal conduction was reduced during sinus
rhythm. After 30 minutes of atrial tachypacing, the du-
ration of induced AF episodes was significantly short-
ened compared with sham controls . Accordingly, we
hypothesize that renal sympathetic denervation could
have a salutary effect on AF patterns in patients with
hypertension by improving blood pressure control and
by reducing central sympathetic cardiac driving.
Renal sympathetic denervation is a newly available
therapeutic option for drug-resistant hypertension. In
2009, the Australian researchers Krum and colleagues
[3] reported for the first time that percutaneous renal
sympathetic denervation acquired positive and sustained
blood pressure reduction in patients with resistant
hypertension. Post-procedure office systolic/diastolic
pressures were reduced by 32/14 mmHg at 24 months,
without serious adverse events. Later, Witkowski and
colleagues [4] studied 10 patients with refractory hyper-
tension and sleep apnea who underwent renal dener-
vation and completed 6-month follow-up evaluations.
Significant decreases in office systolic and diastolic blood
pressures were observed; plasma glucose concentration
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A1C level, as well as the apnea-hypopnea index at
6 months, were also decreased remarkably. In addition
to the known effect on blood pressure, the study by
Brandt and colleagues [5] showed renal denervation sig-
nificantly reduces left ventricular mass and improves
diastolic function. In another study, there was a marked
reduction in muscle and whole-body sympathetic nerve
activity, with a decrease in renal and whole-body nor-
epinephrine spillover [6]. Left ventricle hypertrophy, left
atrial enlargement, high norepinephrine levels, glucose
tolerance abnormality and obstructive sleep apnea are all
recognized as independent risk factors for the deve-
lopment and recurrence of AF. Recently, a case was
reported with renal artery ablation instead of pulmonary
vein ablation in an uncontrolled hypertensive patient
with symptomatic, drug-resistant persistent AF [27]. Six
months later, the patient presented marked improve-
ment in symptoms and exercise capacity, and was still
free of symptoms and in normal sinus rhythm; echocar-
diography showed a progressive decrease of the left atrial
diameter from 45 mm just prior to renal ablation to 40
and 36 mm at 3 and 6 months thereafter, respectively.
Pokushalov and colleagues [9] found that, at 1 year
follow-up, the success rate (that is, being AF free) for the
combined procedure was achieved in 9 of the 13 patients
(69%) treated with pulmonary vein isolation and renal ar-
tery denervation as compared with only 4 of 14 patients
(29%) in those treated with only pulmonary vein isolation.
Should renal artery denervation be part of the ablation
procedure for all patients undergoing catheter ablation
for the treatment of AF, or should renal artery denerv-
ation be performed instead of left atrial ablation? Larger
clinical studies are needed to help answer these ques-
tions. The RSDforAF trial is testing the hypothesis that
RSD is superior to AAD in reducing AF burden and
blood pressure in patients with drug-resistant hyperten-
sion and symptomatic AF.
Trial status
The trial is registered at www.clinicaltrials.gov, registry
number: NCT01713270. The first patient was random-
ized in July 2012. This study is currently recruiting
participants.
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